Humming Bird Power, Precision & Agility

Where to find us

Generic placeholder image
About UCB Ventures
  1. UCB Ventures is a €150 million strategic corporate venture fund established in 2017 to further strengthen UCB's ability to create value from novel insights and technologies that can transform the lives of patients suffering from severe diseases. We make long term investments in early stage companies in the US and Europe. Our portfolio reflects our investment strategy.
  2. We invest in start-ups developing novel therapeutic modalities, platforms/assets that address novel biology, or innovative digital solutions, in areas adjacent to or even beyond UCB's current therapeutic focus. We are seeking breakthrough innovations in next generation cell and gene therapy, regenerative medicine, cell and tissue homeostasis, RNA targeted therapeutics, and patient engagement solutions that significantly improve outcomes.
  3. We are known for our speed and agility, yet thoughtful and sophisticated approach. Above all, we are committed long term investors, working closely with entrepreneurs to bring out the best in our portfolio companies.


ExeVir’s CRO hunt for Phase II/III COVID-19 subQ antibody trial to start midyear, also USD 50– 100m Series B raise

22 Apr 2021. ExeVir Bio will open its doors to CRO pitches mid-year for a Phase II/III trial investigating its
subcutaneously administered neutralizing antibody XVR011 in outpatient COVID-19 patients, CEO
Torsten Mummenbrauer said. Decisions will be made in 2H21 for a 2Q22 trial start, he added.

Neurona Therapeutics Presents Preclinical Data from Lead Cell Therapy Program, Demonstrating Significant Seizure Suppression in Model of Focal Epilepsy

19 Apr 2021. Neurona is a cell therapy company focused on the development of breakthrough treatments for neurological disorders

StrideBio Announces Closing of $81.5M Series B Financing

Research Triangle Park, N.C., Mar. 16, 2021 – StrideBio, Inc., a leading developer of novel engineered adeno-associated virus (AAV) based gene therapies, today announced the closing of an oversubscribed Series B funding round, which raised $81.5 million.

ExeVir Announces Close of US$50 million / EUR42 million Series A Financing

Belgium, March 16th, 2021: ExeVir, which is developing single domain antibody therapies providing broad protection against viral infections, today announces that it has closed its Series A financing raising a total of EUR 42 million / US$50 million. The financing was led by Fund+ with VIB, UCB Ventures, SFPI-FPIM, V-Bio Ventures and new investors SRIW, Noshaq, Vives IUF, SambrInvest, as well as several Belgian family offices.

UCB Ventures and AXA Venture Partners: seeking innovation in digital health

18 Feb 2021. In this interview, UCB Ventures Partner, Delphine Hajaji, connects with François Robinet, Founding and Managing Partner at AXA Venture Partners, to tell us more about why both organizations decided to collaborate. In particular, why AXA Venture Partners chose to open their Fund to other investors and why UCB Ventures became one of their first external investor.

Syndesi Therapeutics announces positive results from two additional Phase I studies of its novel SV2A modulator SDI-118, providing strong support for the initiation of further clinical trials in cognitive impairment

27 Jan 2021 — Syndesi Therapeutics SA, a clinical stage biotechnology company developing novel modulators of the synaptic vesicle protein SV2A for the treatment of cognitive impairment, announces results from two Phase I studies of its lead compound SDI-118.

Locanabio Announces $100 Million Series B Financing to Advance Portfolio of Novel RNATargeted Gene Therapies for Neurodegenerative, Neuromuscular and Retinal Diseases

14 Dec 2020 — Locanabio, Inc., an RNA-targeting gene therapy company focused on developing life-changing therapies for patients with severe neurodegenerative, neuromuscular and retinal diseases, today announced a $100 million Series B financing.